An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-la Roche sponsored pertuzumab study

Trial Profile

An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-la Roche sponsored pertuzumab study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab; Vinorelbine
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 Feb 2015 Planned End Date changed from 1 Jan 2025 to 1 Feb 2025 as reported by ClinicalTrials.gov record.
    • 05 Feb 2015 Planned primary completion date changed from 1 Jan 2025 to 1 Feb 2025 as reported by ClinicalTrials.gov record.
    • 19 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top